Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
DIET / STATE OF THE ART PAPER
May nutrients and dietary supplements influence the gut-lung microbiota axis in chronic obstructive pulmonary disease and exacerbations?
1
Laboratory of InterDisciplinary Research Applied to Medicine (DReAM), University of Salento and ASL LE (Local Health Authority) at the “V. Fazzi” Hospital, Lecce, Italy
2
Laboratory of Advanced Data Analysis for Medicine (ADAM), Department of Mathematics and Physics “E. De Giorgi”, University of Salento, Lecce, Italy
3
Department of Rehabilitation, Respiratory Care Unit, ASL/Lecce, Italy
Submission date: 2020-03-29
Final revision date: 2020-08-07
Acceptance date: 2020-08-09
Online publication date: 2020-11-04
Publication date: 2026-06-30
Arch Med Sci 2026;22(3):1259-1274
KEYWORDS
TOPICS
ABSTRACT
There is increasing evidence that microbial community structure and diversity are associated with disease severity and clinical outcomes, both in stable chronic obstructive pulmonary disease (COPD) and in exacerbations. New evidence has confirmed that the gut-lung axis – the cross-talk between the gut and the lung – is a bi-directional condition that is a continuous blood communication between the two sits that, in this way, would be able to modulate each other's local immune response and the composition of the respective microbiota. However, although it is clear that the gut microbiota influences inflammation in the peripheral system, what happens in the lung is still poorly understood. As malnutrition is an important factor in COPD, nutritional support might be a strong component of disease management and prevention. In this review, we tried to elucidate the role of diet and dietary supplementation affecting the lung microbiota with respect to stable COPD and exacerbation.
REFERENCES (208)
1.
World Health Organization (WHO). Global Burden of Disease: 2004 Update. WHO: Geneva; 2008.
2.
GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2018 report. Global Initiative for Chronic Obstructive Lung Disease; 2018.
3.
Mayhew D, Devos N, Lambert C, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax 2018; 73: 422-30.
4.
Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-65.
5.
Yang IA, Brown JL, George J, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Med J Aust 2017; 207: 436-42.
6.
Simpson JL, Powell H, Baines KJ, et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One 2014; 9: e105609.
7.
Vaughan A, Frazer ZA, Hansbro PM, Yang IA. COPD and the gut-lung axis: the therapeutic potential of fibre. J Thorac Dis 2019; 11: S2173-80.
8.
Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med 2016; 8: 51.
9.
Gomes AC, Hoffmann C, Mota JF. The human gut microbiota: metabolism and perspective in obesity. Gut Microbes 2018; 9: 308-25.
10.
Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011; 184: 957-63.
11.
Dickson RP, Erb-Downward JR, Martinez FJ, Huffnagle GB. The microbiome and the respiratory tract. Annu Rev Physiol 2016; 78: 481-504.
12.
Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS One 2011; 6: e16384.
13.
Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Expert Rev Respir Med 2013; 7: 245-57.
14.
Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross- talk in mucosal inflammatory disease. Mucosal Immunol 2012; 5: 7-18.
15.
Budden KF, Gellatly SL, Wood DLA, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 2017; 15: 55-63.
16.
Keely S, Hansbro PM. Lung-gut cross talk: a potential mechanism for intestinal dysfunction in patients with COPD. Chest 2014; 145: 199-200.
17.
Fricker M, Goggins BJ, Mateer S, et al. Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction. JCI Insight 2018; 3: e94040.
18.
Mateer SW, Maltby S, Marks E, et al. Potential mechanisms regulating pulmonary pathology in inflammatory bowel disease. J Leukoc Biol 2015; 98: 727-37.
19.
Mateer SW, Mathe A, Bruce J, et al. IL-6 drives neutrophil-mediated pulmonary inflammation associated with bacteremia in murine models of colitis. Am J Pathol 2018; 188: 1625-39.
20.
Liu G, Mateer SW, Hsu A, et al. Platelet activating factor receptor regulates colitis-induced pulmonary inflammation through the NLRP3 inflammasome. Mucosal Immunol 2019; 12: 862-73.
21.
Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014; 20: 159-66.
22.
Shaheen SO, Jameson KA, Syddall HE, et al. The relationship of dietary patterns with adult lung function and COPD. Eur Respir J 2010; 36: 277-84.
23.
Young RP, Hopkins RJ. Is the “western diet” a new smoking gun for chronic obstructive pulmonary disease? Ann Am Thorac Soc 2018; 15: 662-3.
24.
Chassaing B, Vijay-Kumar M, Gewirtz AT. How diet can impact gut microbiota to promote or endanger health. Curr Opin Gastroenterol 2017; 33: 417-21.
25.
Arumugam M, Raes J, Pelletier E, et al. Enterotypes in the landscape of gut microbial community composition. Nature 2013; 3: 1-12.
26.
Binda C, Lopetuso LR, Rizzatti G, Gibiino G, Cennamo V, Gasbarrini A. Actinobacteria: a relevant minority for the maintenance of gut homeostasis. Dig Liver Dis 2018; 50: 421-8.
27.
Sullivan A, Hunt E, MacSharry J, Murphy DM. The microbiome and the pathophysiology of asthma. Respir Res 2016; 17: 163.
28.
Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010; 5: e8578.
29.
Di Cicco ME, Licari A, Leone M, et al. Impatto del microbioma (polmonare e intestinale) sull’asma. Riv di Immunol e Allergol Pediatr 2018; 2: 26-32.
30.
Dickson RP, Erb-Downward JR, Freeman CM, et al. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann Am Thorac Soc 2015; 12: 821-30.
31.
Tulic MK, Piche T, Verhasselt V. Lung-gut cross-talk: evidence, mechanisms and implications for the mucosal inflammatory diseases. Clin Exp Allergy 2016; 46: 519-28.
32.
Dickson RP, Huffnagle GB. The lung microbiome: new principles for respiratory bacteriology in health and disease. PLoS Pathog 2015; 11: e1004923.
33.
Toraldo DM, Conte L. Influence of the lung microbiota dysbiosis in chronic obstructive pulmonary disease exacerbations: the controversial use of corticosteroid and antibiotic treatments and the role of eosinophils as a disease marker. J Clin Med Res 2019; 11: 667-75.
34.
Wu H, Kuzmenko A, Wan S, et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003; 111: 1589-602.
35.
Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-8.
36.
Robles Alonso V, Guarner F. Intestinal microbiota composition in adults. In: Probiotic Bacteria and Their Effect on Human Health and Well-Being. Karger Publishers 2013; 107: 17-24.
37.
Marsland BJ, Trompette A, Gollwitzer ES. The gut-lung axis in respiratory disease. Ann Am Thorac Soc 2015; 12: S150-6.
38.
Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the ‘healthy’ smoker and in COPD. PLoS One 2011; 6: e16384.
39.
Brandl K, Plitas G, Mihu CN, et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 2008; 455: 804-7.
40.
Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends Microbiol 2008; 16: 107-14.
41.
Stecher B, Hardt WD. Mechanisms controlling pathogen colonization of the gut. Curr Opin Microbiol 2011; 14: 82-91.
42.
Abt MC, Osborne LC, Monticelli LA, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 2012; 37: 158-70.
43.
Ganal SC, Sanos SL, Kallfass C, et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 2012; 37: 171-86.
44.
Inagaki H, Suzuki T, Nomoto K, Yoshikai Y. Increased susceptibility to primary infection with Listeria monocytogenes in germfree mice may be due to lack of accumulation of L-selectin+ CD44+ T cells in sites of inflammation. Infect Immun 1996; 64: 3280-7.
45.
Clarke TB. Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via Nod-like receptor ligands. Infect Immun 2014; 82: 4596-606.
46.
Man WH, de Steenhuijsen Piters WAA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol 2017; 15: 259-70.
47.
Dekaboruah E, Suryavanshi MV, Chettri D, Verma AK. Human microbiome: an academic update on human body site specific surveillance and its possible role. Arch Microbiol 2020; 202: 2147-67.
48.
Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014; 384: 691-702.
49.
Garcha DS, Thurston SJ, Patel ARC, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012; 67: 1075-80.
50.
Galiana A, Aguirre E, Rodriguez JC, et al. Sputum microbiota in moderate versus severe patients with COPD. Eur Respir J 2014; 43: 1787-90.
51.
Biesbroek G, Tsivtsivadze E, Sanders EAM, et al. Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children. Am J Respir Crit Care Med 2014; 190: 1283-92.
52.
Bomar L, Brugger SD, Yost BH, Davies SS, Lemon KP. Corynebacterium accolens releases antipneumococcal free fatty acids from human nostril and skin surface triacylglycerols. MBio 2016; 7: e01725-15.
53.
Pettigrew MM, Laufer AS, Gent JF, Kong Y, Fennie KP, Metlay JP. Upper respiratory tract microbial communities, acute otitis media pathogens, and antibiotic use in healthy and sick children. Appl Environ Microbiol 2012; 78: 6262-70.
54.
Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-20.
55.
Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-505.
56.
Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108: 43S-52S.
57.
Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J 2016; 47: 1082-92.
58.
Millares L, Ferrari R, Gallego M, et al. Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2014; 33: 1101-11.
59.
Dy R, Sethi S. The lung microbiome and exacerbations of COPD. Curr Opin Pulm Med 2016; 22: 196-202.
60.
Toivonen L, Hasegawa K, Waris M, et al. Early nasal microbiota and acute respiratory infections during the first years of life. Thorax 2019; 74: 592-9.
61.
Haberman Y, Tickle TL, Dexheimer PJ, et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest 2014; 124: 3617-33.
62.
Ahmed B, Cox MJ, Cuthbertson L. Growing up with your airway microbiota: a risky business. Thorax 2019; 74: 525-6.
63.
O’Dwyer DN, Dickson RP, Moore BB. The lung microbiome, immunity, and the pathogenesis of chronic lung disease. J Immunol 2016; 196: 4839-47.
64.
Jaspers I. Cigarette smoke effects on innate immune mechanisms in the nasal mucosa. Potential effects on the microbiome. Ann Am Thorac Soc 2014; 11: S38-42.
65.
Heijink IH, Brandenburg SM, Postma DS, van Oosterhout AJM. Cigarette smoke impairs airway epithelial barrier function and cell-cell contact recovery. Eur Respir J 2012; 39: 419-28.
66.
Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease. JAMA 2013; 309: 2223.
67.
McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997; 111: 732-43.
68.
Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 48-55.
69.
Taylor SL, Leong LEX, Mobegi FM, et al. Long-term azithromycin reduces haemophilus influenzae and increases antibiotic resistance in severe asthma. Am J Respir Crit Care Med 2019; 200: 309-17.
70.
Segal LN, Clemente JC, Wu BG, et al. Randomised, double- blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax 2017; 72: 13-22.
71.
Denner DR, Sangwan N, Becker JB, et al. Corticosteroid therapy and airflow obstruction influence the bronchial microbiome, which is distinct from that of bronchoalveolar lavage in asthmatic airways. J Allergy Clin Immunol 2016; 137: 1398-405.
72.
Huang YJ, Boushey HA. The microbiome in asthma. J Allergy Clin Immunol 2015; 135: 25-30.
73.
Goleva E, Jackson LP, Harris JK, et al. The effects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med 2013; 188: 1193-201.
74.
Durack J, Lynch SV, Nariya S, et al. Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. J Allergy Clin Immunol 2017; 140: 63-75.
75.
Ozturk AB, Turturice BA, Perkins DL, Finn PW. The potential for emerging microbiome-mediated therapeutics in asthma. Curr Allergy Asthma Rep 2017; 17: 62.
76.
Ezzell L, Jensen GL. Malnutrition in chronic obstructive pulmonary disease. Am J Clin Nutr 2000; 72: 1415-6.
77.
Celli B, Wouters E, Ambrosino N, et al. Nutrition and nutraceuticals in chronic lung disease. Work Gr Nutr Nutraceuticals Chronic Lung Dis 2017; 1: 1-15.
78.
Vermeeren MAP, Creutzberg EC, Schols AMWJ, et al. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med 2006; 100: 1349-55.
79.
Rutten EP, Franssen FM, Engelen MP, Wouters EF, Deutz NE, Schols AM. Greater whole-body myofibrillar protein breakdown in cachectic patients with chronic obstructive pulmonary disease. Am J Clin Nutr 2006; 83: 829-34.
80.
Taivassalo T, Hussain SNA. Contribution of the mitochondria to locomotor muscle dysfunction in patients with COPD. Chest 2016; 149: 1302-12.
81.
Puente-Maestu L, Lázaro A, Humanes B. Metabolic derangements in COPD muscle dysfunction. J Appl Physiol 2013; 114: 1282-90.
82.
Marinari S, Manigrasso MR, De Benedetto F. Effects of nutraceutical diet integration, with coenzyme Q10 (Q-Ter multicomposite) and creatine, on dyspnea, exercise tolerance, and quality of life in COPD patients with chronic respiratory failure. Multidiscip Respir Med 2013; 8: 40.
83.
Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Hear Fail 2014; 2: 641-9.
84.
Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Nutrition 2010; 26: 250-4.
85.
Budden KF, Shukla SD, Rehman SF, et al. Functional effects of the microbiota in chronic respiratory disease. Lancet Respir Med 2019; 7: 907-20.
86.
Wood LG, Li Q, Scott HA, et al. Saturated fatty acids, obesity, and the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in asthmatic patients. J Allergy Clin Immunol 2019; 143: 305-15.
87.
Rutting S, Zakarya R, Bozier J, et al. Dietary fatty acids amplify inflammatory responses to infection through p38 MAPK signaling. Am J Respir Cell Mol Biol 2019; 60: 554-68.
88.
Martinez KB, Leone V, Chang EB. Western diets, gut dysbiosis, and metabolic diseases: are they linked? Gut Microbes 2017; 8: 130-42.
89.
Kaidar-Person O, Person B, Szomstein S, Rosenthal RJ. Nutritional deficiencies in morbidly obese patients: a new form of malnutrition? Part A: vitamins. Obes Surg 2008; 18: 870-6.
90.
Mekary RA. A higher overall diet quality is inversely associated with the risk of chronic obstructive pulmonary disease (COPD) in men and women. Evid Based Med 2016; 21: 36.
91.
Kan H, Stevens J, Heiss G, Rose KM, London SL. Dietary fiber, lung function, and chronic obstructive pulmonary disease in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2008; 167: 570-8.
92.
Varraso R, Willett WC, Camargo CA. Prospective study of dietary fiber and risk of chronic obstructive pulmonary disease among US women and men. Am J Epidemiol 2010; 171: 776-84.
93.
Szmidt MK, Kaluza J, Harris HR, Linden A, Wolk A. Long-term dietary fiber intake and risk of chronic obstructive pulmonary disease: a prospective cohort study of women. Eur J Nutr 2020; 59: 1869-79.
94.
Keranis E, Makris D, Rodopoulou P, et al. Impact of dietary shift to higher-antioxidant foods in COPD: a randomised trial. Eur Respir J 2010; 36: 774-80.
95.
Scoditti E, Massaro M, Garbarino S, Toraldo DM. Role of diet in chronic obstructive pulmonary disease prevention and treatment. Nutrients 2019; 11: 1357.
96.
Krzysztoszek J, Kleka P, Laudańska-Krzemińska I. Assessment of selected nutrient intake by Polish preschool children compared to dietary recommendations: a meta-analysis. Arch Med Sci 2020; 16: 635-47.
97.
Trichopoulou A, Martínez-González MA, Tong TYN, et al. Definitions and potential health benefits of the Mediterranean diet: views from experts around the world. BMC Med 2014; 12: 112.
98.
Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta- analysis. BMJ 2008; 337: 673-5.
99.
Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461: 1282-6.
100.
Kaneko T, Mori H, Iwata M, Meguro S. Growth stimulator for bifidobacteria produced by Propionibacterium freudenreichii and several intestinal bacteria. J Dairy Sci 1994; 77: 393-404.
101.
Xie S, Liu J, Li L, Qiao C. Biodegradation of malathion by Acinetobacter johnsonii MA19 and optimization of cometabolism substrates. J Environ Sci 2009; 21: 76-82.
102.
Flint HJ, Bayer EA, Rincon MT, Lamed R, White BA. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat Rev Microbiol 2008; 6: 121-31.
103.
Ratajczak W, Rył A, Mizerski A, Walczakiewicz K, Sipak O, Laszczyńska M. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim Pol 2019; 66: 1-12.
104.
Young RP, Hopkins RJ, Marsland B. The gut-liver-lung axis. Modulation of the innate immune response and its possible role in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2016; 54: 161-9.
105.
Cummings JH, Pomare EW, Branch HWJ, Naylor CPE, MacFarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987; 28: 1221-7.
106.
Esposito K, Giugliano D. Whole-grain intake cools down inflammation. Am J Clin Nutr 2006; 83: 1440-1.
107.
Kan H, Stevens J, Heiss G, Rose KM, London SJ. Dietary fiber, lung function, and chronic obstructive pulmonary disease in the atherosclerosis risk in communities study. Am J Epidemiol 2007; 167: 570-8.
108.
Kaluza J, Harris H, Wallin A, Linden A, Wolk A. Dietary fiber intake and risk of chronic obstructive pulmonary disease: a prospective cohort study of men. Epidemiology 2018; 29: 254-60.
109.
Ghosh TS, Rampelli S, Jeffery IB, et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. Gut 2020; 69: 1218-28.
110.
Tabak C, Smit HA, Heederik D, Ocke MC, Kromhout D. Diet and chronic obstructive pulmonary disease: independent beneficial effects of fruits, whole grains, and alcohol (the MORGEN study). Clin Exp Allergy 2001; 31: 747-55.
111.
Root MM, Houser SM, Anderson JJB, Dawson HR. Healthy Eating Index 2005 and selected macronutrients are correlated with improved lung function in humans. Nutr Res 2014; 34: 277-84.
112.
Jacobs DR, Andersen LF, Blomhoff R. Whole-grain consumption is associated with a reduced risk of noncardiovascular, noncancer death attributed to inflammatory diseases in the Iowa Women’s Health Study. Am.
114.
Rowland I, Gibson G, Heinken A, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr 2018; 57: 1-24.
115.
Lin YC, Wu TC, Chen PY, Hsieh LY, Yeh SL. Comparison of plasma and intake levels of antioxidant nutrients in patients with chronic obstructive pulmonary disease and healthy people in Taiwan: a case-control study. Asia Pac J Clin Nutr 2010; 19: 393-401.
116.
Laudisio A, Costanzo L, Di Gioia C, et al. Dietary intake of elderly outpatients with chronic obstructive pulmonary disease. Arch Gerontol Geriatr 2016; 64: 75-81.
117.
Van De Bool C, Mattijssen-Verdonschot C, Van Melick PPMJ, et al. Quality of dietary intake in relation to body composition in patients with chronic obstructive pulmonary disease eligible for pulmonary rehabilitation. Eur J Clin Nutr 2014; 68: 159-65.
118.
Tug T, Karatas F, Terzi SM. Antioxidant vitamins (A, C and E) and malondialdehyde levels in acute exacerbation and stable periods of patients with chronic obstructive pulmonary disease. Clin Investig Med 2004; 27: 123-8.
119.
Maggini S, Wintergerst ES, Beveridge S, Hornig DH. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br J Nutr 2007; 98: S29-35.
120.
Pierre JF, Hinterleitner R, Bouziat R, et al. Dietary antioxidant micronutrients alter mucosal inflammatory risk in a murine model of genetic and microbial susceptibility. J Nutr Biochem 2018; 54: 95-104.
121.
Mandal S, Godfrey KM, McDonald D, et al. Fat and vitamin intakes during pregnancy have stronger relations with a proinflammatory maternal microbiota than does carbohydrate intake. Microbiome 2016; 4: 1-11.
122.
De Batlle J, Barreiro E, Romieu I, et al. Dietary modulation of oxidative stress in chronic obstructive pulmonary disease patients. Free Radic Res 2010; 44: 1296-303.
123.
Rodríguez-Rodríguez E, Ortega RM, Andrés P, et al. Antioxidant status in a group of institutionalised elderly people with chronic obstructive pulmonary disease. Br J Nutr 2016; 115: 1740-7.
124.
Walda IC, Tabak C, Smit HA, et al. Diet and 20-year chronic obstructive pulmonary disease mortality in middle-aged men from three European countries. Eur J Clin Nutr 2002; 56: 638-43.
125.
Agler AH, Kurth T, Gaziano JM, Buring JE, Cassano PA. Randomised vitamin E supplementation and risk of chronic lung disease in the Women’s Health Study. Thorax 2011; 66: 320-5.
126.
Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
127.
Kanhere M, Chassaing B, Gewirtz AT, Tangpricha V. Role of vitamin D on gut microbiota in cystic fibrosis. J Steroid Biochem Mol Biol 2018; 175: 82-7.
128.
Tabatabaeizadeh SA, Tafazoli N, Ferns G, Avan A, Ghayour-Mobarhan M. Vitamin D, the gut microbiome and inflammatory bowel disease. J Res Med Sci 2018; 23: 75.
129.
Sun J. Dietary vitamin D, vitamin D receptor, and microbiome. Curr Opin Clin Nutr Metab Care 2018; 21: 471-4.
130.
Clark A, Mach N. Role of vitamin D in the hygiene hypothesis: the interplay between vitamin D, vitamin D receptors, gut microbiota, and immune response. Front Immunol 2016; 7: 627.
131.
Ardesia M, Ferlazzo G, Fries W. Vitamin D and inflammatory bowel disease. BioMed Res Int 2015; 2015: 470805.
132.
Schäffler H, Herlemann DP, Klinitzke P, et al. Vitamin D administration leads to a shift of the intestinal bacterial composition in Crohn’s disease patients, but not in healthy controls. J Dig Dis 2018; 19: 225-34.
133.
Jacobs C, Hutton B, Ng T, Shorr R, Clemons M. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist 2015; 20: 210-23.
134.
Revuelta Iniesta R, Rush R, Paciarotti I, et al. Systematic review and meta-analysis: prevalence and possible causes of vitamin D deficiency and insufficiency in pediatric cancer patients. Clin Nutr 2016; 35: 95-108.
135.
Meeker S, Seamons A, Maggio-Price L, Paik J. Protective links between vitamin D, inflammatory bowel disease and colon cancer. World J Gastroenterol 2016; 22: 933-48.
136.
Kanhere M, He J, Chassaing B, et al. Bolus weekly vitamin D3 supplementation impacts gut and airway microbiota in adults with cystic fibrosis: a double-blind, randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 2018; 103: 564-74.
137.
Ciubotaru I, Green SJ, Kukreja S, Barengolts E. Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans. Transl Res 2015; 166: 401-11.
138.
Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017; 356: i6583.
139.
Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. Thorax 2019; 74: 337-45.
140.
Janssens W, Bouillon R, Claes B, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010; 65: 215-20.
141.
Selma MV, Espín JC, Tomás-Barberán FA. Interaction between phenolics and gut microbiota: role in human health. J Agric Food Chem 2009; 57: 6485-501.
142.
Parkar SG, Stevenson DE, Skinner MA. The potential influence of fruit polyphenols on colonic microflora and human gut health. Int J Food Microbiol 2008; 124: 295-8.
143.
Etxeberria U, Arias N, Boqué N, et al. Reshaping faecal gut microbiota composition by the intake of trans-.
144.
resveratrol and quercetin in high-fat sucrose diet-fed rats. J Nutr Biochem 2015; 26: 651-60.
145.
Taira T, Yamaguchi S, Takahashi A, et al. Dietary polyphenols increase fecal mucin and immunoglobulin A and ameliorate the disturbance in gut microbiota caused by a high fat diet. J Clin Biochem Nutr 2015; 57: 212-6.
146.
Wang L, Zeng B, Liu Z, et al. Green tea polyphenols modulate colonic microbiota diversity and lipid metabolism in high-fat diet treated HFA mice. J Food Sci 2018; 83: 864-73.
147.
Seo DB, Jeong HW, Cho D, et al. Fermented green tea extract alleviates obesity and related complications and alters gut microbiota composition in diet-induced obese mice. J Med Food 2015; 18: 549-56.
148.
Potì F, Santi D, Spaggiari G, Zimetti F, Zanotti I. Polyphenol health effects on cardiovascular and neurodegenerative disorders: a review and meta-analysis. Int J Mol Sci 2019; 20: 351.
149.
Tabak C, Arts ICW, Smit HA, Heederik D, Kromhout D. Chronic obstructive pulmonary disease and intake of catechins, flavonols, and flavones. Am J Respir Crit Care Med 2001; 164: 61-4.
150.
Lu MC, Yang MD, Li PC, et al. Effect of oligomeric proanthocyanidin on the antioxidant status and lung function of patients with chronic obstructive pulmonary disease. In Vivo 2018; 32: 753-8.
151.
Pounis G, Arcari A, Costanzo S, et al. Favorable association of polyphenol-rich diets with lung function: cross-sectional findings from the Moli-sani study. Respir Med 2018; 136: 48-57.
152.
Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006; 40: 445-53.
153.
Deacon SJ, Vincent EE, Greenhaff PL, et al. Randomized controlled trial of dietary creatine as an adjunct therapy to physical training in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 233-9.
154.
Clarke SF, Murphy EF, Lucey AJ, et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut 2014; 63: 1913-20.
155.
Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med 2008; 233: 674-88.
156.
Massaro M, Scoditti E, Carluccio MA, De Caterina R. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot Essent Fat Acids 2008; 79: 109-15.
157.
Cândido FG, Valente FX, Grześkowiak ŁM, Boroni Moreira AP, Mayumi Usuda Prado Rocha D, de Cassia Goncalves Alfenas R. Impact of dietary fat on gut microbiota and low-grade systemic inflammation: mechanisms and clinical implications on obesity. Int J Food Sci Nutr 2018; 69: 125-43.
158.
Watson H, Mitra S, Croden FC, et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut 2018; 67: 1974-83.
159.
Costantini L, Molinari R, Farinon B, Merendino N. Impact of omega-3 fatty acids on the gut microbiota. Int J Mol Sci 2017; 18: 2645.
160.
Bidu C, Escoula Q, Bellenger S, et al. The transplantation of V3 PUFA-altered gut microbiota of fat-1 mice to wild-type littermates prevents obesity and associated metabolic disorders. Diabetes 2018; 67: 1512-23.
161.
Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AMWJ. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
162.
Fulton AS, Hill AM, Williams MT, Howe PRC, Coates AM. Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease: a systematic review. Nutr Rev 2015; 73: 612-23.
163.
Varraso R, Barr RG, Willett WC, Speizer FE, Camargo CA. Fish intake and risk of chronic obstructive pulmonary disease in 2 large US cohorts. Am J Clin Nutr 2015; 101: 354-61.
164.
Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009; 14: 141-53.
165.
Jazayeri SD, Mustafa S, Manap MY, et al. Survival of bifidobacteria and other selected intestinal bacteria in TPY medium supplemented with curcumin as assessed in vitro. Int J Probiotics Prebiotics 2009; 4: 15-22.
166.
Tan S, Rupasinghe TWT, Tull DL, et al. Degradation of curcuminoids by in vitro pure culture fermentation. J Agric Food Chem 2014; 62: 11005-15.
167.
Di Meo F, Margarucci S, Galderisi U, Crispi S, Peluso G. Curcumin, gut microbiota, and neuroprotection. Nutrients 2019; 11: 2426.
168.
Zam W. Gut microbiota as a prospective therapeutic target for curcumin: a review of mutual influence. J Nutr Metab 2018; 2018: 1367984.
169.
Feng W, Wang H, Zhang P, et al. Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats. Biochim Biophys Acta Gen Subj 2017; 1861: 1801-12.
170.
Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500: 541-6.
171.
Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature 2013; 500: 585-8.
172.
Ng TP, Niti M, Yap KB, Tan WC. Curcumins-rich curry diet and pulmonary function in Asian older adults. PLoS One 2012; 7: e51753.
173.
FAO/WHO working group. Guidelines for the evaluation of probiotics in food. London: FAO/WHO; 2002, pp. 1-11.
175.
Neunez M, Goldman M, Ghezzi P. Online information on probiotics: does it match scientific evidence? Front Med 2020; 6: 1-7.
176.
European U. Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. Off J Eur Union L404/9-L404/25; 2006.
177.
Wieërs G, Belkhir L, Enaud R, et al. How probiotics affect the microbiota. Front Cell Infect Microbiol 2020; 9: 454.
178.
Gerritsen J, Smidt H, Rijkers GT, De Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. Gen Nutr 2011; 6: 209-40.
179.
Özdemir Ö. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol 2010; 160: 295-304.
180.
Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-5.
181.
Makino H. Bifidobacterial strains in the intestines of newborns originate from their mothers. Biosci Microbiota Food Health 2018; 37: 79-85.
182.
Milani C, Duranti S, Bottacini F, et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev 2017; 81: e00036-17.
183.
Jacobson A, Lam L, Rajendram M, et al. A gut commensal- produced metabolite mediates colonization resistance to Salmonella infection. Cell Host Microbe 2018; 24: 296-307.e7.
184.
Costa Liboredo J, Anastácio LR, do Carmo Gouveia Pelúzio M, et al. Effect of probiotics on the development of dimethylhydrazine-induced preneoplastic lesions in the mice colon. Acta Cir Bras 2013; 28: 367-72.
185.
Bertkova I, Hijova E, Chmelarova A, et al. The effect of probiotic microorganisms and bioactive compounds on chemically induced carcinogenesis in rats. Neoplasma 2010; 57: 422-8.
186.
Yang Y, Xia Y, Chen H, et al. The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial. Oncotarget 2016; 7: 8432-40.
187.
Liang S, Xu L, Zhang D, Wu Z. Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. Turk J Gastroenterol 2016; 27: 227-59.
188.
Fan YJ, Chen SJ, Yu YC, Si JM, Liu B. A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial. J Zhejiang Univ Sci B 2006; 7: 987-91.
189.
Wang W, Shi LP, Shi L, Xu L. Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease. Zhonghua Nei Ke Za Zhi 2018; 57: 101-6 [In Chinese].
190.
Hu X, Wang T, Li W, Jin F, Wang L. Effects of NS lactobacillus strains on lipid metabolism of rats fed a high-cholesterol diet. Lipids Health Dis 2013; 12: 67.
191.
Qian L, Gao R, Huang J, Qin H. Supplementation of triple viable probiotics combined with dietary intervention is associated with gut microbial improvement in humans on a high-fat diet. Exp Ther Med 2019; 18: 2262-70.
192.
Iwase T, Uehara Y, Shinji H, et al. Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 2010; 465: 346-9.
193.
Ditz B, Christenson S, Rossen J, et al. Sputum microbiome profiling in COPD: beyond singular pathogen detection. Thorax 2020; 75: 338-44.
194.
Di Pierro F, Risso P, Poggi E, et al. Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects. Minerva Pediatr 2018; 70: 240-5.
195.
Gregori G, Righi O, Risso P, et al. Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag 2016; 12: 87-92.
196.
Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med 2012; 5: 991-7.
197.
Di Pierro F, Di Pasquale D, Di Cicco M. Oral use of streptococcus salivarius k12 in children with secretory otitis media: preliminary results of a pilot, uncontrolled study. Int J Gen Med 2015; 8: 303-8.
198.
Humphreys GJ, McBain AJ. Antagonistic effects of Streptococcus and Lactobacillus probiotics in pharyngeal biofilms. Lett Appl Microbiol 2019; 68: 303-12.
199.
Noverr MC, Noggle RM, Toews GB, Huffnagle GB. Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect Immun 2004; 72: 4996-5003.
200.
Douillard FP, de Vos WM. Biotechnology of health-promoting bacteria. Biotechnol Adv 2019; 37: 107369.
201.
Pasolli E, De Filippis F, Mauriello IE, et al. Large-scale genome-wide analysis links lactic acid bacteria from food with the gut microbiome. Nat Commun 2020; 11: 2610.
202.
Uriot O, Denis S, Junjua M, Roussel Y, Dary-Mourot A, Blanquet-Diot S. Streptococcus thermophilus: from yogurt starter to a new promising probiotic candidate? J Funct Foods 2017; 37: 74-89.
203.
Song AAL, In LLA, Lim SHE, Rahim RA. A review on Lactococcus lactis: from food to factory. Microb Cell Fact 2017; 16: 55.
204.
Nakamura S, Morimoto YV, Kudo S. A lactose fermentation product produced by Lactococcus lactis subsp. lactis, acetate, inhibitsthe motility of flagellated pathogenic bacteria. Microbiology (Reading) 2015; 161: 701-7.
205.
Mortaz E, Adcock IM, Ricciardolo FLM, et al. Anti-inflammatory effects of Lactobacillus rahmnosus and Bifidobacterium breve on cigarette smoke activated human macrophages. PLoS One 2015; 10: e0136455.
206.
Gabryszewski SJ, Bachar O, Dyer KD, et al. Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. J Immunol 2011; 186: 1151-61.
207.
Tomosada Y, Chiba E, Zelaya H, et al. Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. BMC Immunol 2013; 14: 40.
208.
Schols AM, Ferreira IM, Franssen FM, et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J 2014; 44: 1504-20.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
